Pay in 4 interest-free payments of $5.16 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
This does NOT mean that every person living with obesity will develop cancer
Tirzepatide is administered subcutaneously once weekly at doses ranging from 2.5 mg to 15 mg, with gradual dose escalation recommended to minimize gastrointestinal adverse effects
A drug used for type 2 diabetes and weight loss could reduce the severity of obstructive sleep apnoea (OSA) in people with obesity, research suggests, raising the possibility of the first pharmaceutical treatment for the condition
For a deeper look at vascular and cardiometabolic risk, see our pages on Preventive Cardiology and Silent Heart Disease Detection, Metabolic Health and Longevity Medicine, and ApoB and Longevity
US$ 22.75
US$ 25.32
US$ 20.82
US$ 28.98
US$ 20.97
